Quadrant Biosciences
OperatingQuadrant Biosciences Inc
Biotech · Founded 2015
Improving the lives of children by diagnosing autism earlier
Financials
FY2018–FY2022 · from SEC filings · hover any figure for its sourceFigures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Pre-money — the valuation set before each round’s money came inBlue bars are the pre-money valuation the company stated for a priced round.
Cap table
Share counts as of Feb 14, 2020| Class | Outstanding | Votes / share | Share of total | Last price |
|---|---|---|---|---|
| Common Stock | 88,647,425 | — | 100.0% | $3.00Mar 2020 |
Principal holders% as the filing states it, Apr 28, 2023
- James Croke2,020,398 shares6.02%of company
- Richard Bongo1,204,266 shares5.28%of company
Sold to the crowd
- Reg A+ · Mar 2020316,217 Common Stock at $3.00$948.7K
- Reg CF · Oct 2020$416.6K
From the company's SEC filings: share counts per class, each class's voting and conversion terms, and the holders of 20% or more that Form C requires (officers and 10%+ holders on Form 1-A). Filings name only large holders, so most owners — including crowd investors — are not listed, and a holder's percentage may be of its own class rather than of the whole company. Prices and crowd share counts are in today's share terms — adjusted for splits and conversions since they were sold. Hover a figure for its filing.
Fundraising history
Team
23 peopleShow 14 more peopleShow fewer
Names and titles as disclosed on SEC Form C, SEC Form 1-A. Bios and photos come from the platform campaign page and may be out of date.
Reg CF annual-report compliance
Filed 3 of 6 annual reports (FY2020–FY2025)
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
View all 28 filings on EDGAR- Form DNov 2, 20230001644600-23-000181EDGAR
- Form 1-SASep 28, 20230001104659-23-104367EDGAR
- Form DAug 8, 20230001644600-23-000136EDGAR
- Form C-ARApr 28, 20230001644600-23-000076EDGAR
- Form 1-KApr 28, 20230001104659-23-052864EDGAR
- Form 1-SASep 27, 20220001104659-22-103189EDGAR
- Form C-ARMay 2, 20220001104659-22-054006EDGAR
- Form 1-KApr 29, 20220001104659-22-053030EDGAR
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.